A pilot, open label, randomised clinical trial assessing the 12 week immunological response in HIV-1 failing subjects receiving monotherapy with emtricitabine 200 mg once a day or emtricitabine 200 mg once a week or lamivudine 300 mg once a day

Registry ID

EUCTR2006-001681-16

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

FONDAZIONE NADIR ONLUS

Start date

2006-06-06

Last update

2026-08-16

Conditions

• HIV-Infection

Summary

The general aim of the BREAK study is to evaluate whether there is a difference in the 12 week immunological response in HIV-1 failing subjects receiving monotherapy with emtricitabine EMTRIVA 200 mg once a day or emtricitabine EMTRIVA 200 mg once a week or lamivudine EPIVIR 300 mg once a day

Locations

• , , Italy

View on source registry